The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549 **FORM D** 

# OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
OUC (ET LID N )	Previous	П.,	
CIK (Filer ID Number)	Names	None	Entity Type
<u>0001183765</u>		O PHARMACEUTICALS	X Corporation
Name of Issuer	INC		Limited Partnership
Molecular Templates, Inc.		armaceuticals, Inc.	Limited Liability Company
Jurisdiction of Incorporation/Organi	ization		H
DELAWARE			General Partnership
Year of Incorporation/Organization			Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify	Year)		
Yet to Be Formed			
2. Principal Place of Business an	d Contact Information		
Name of Issuer			
Molecular Templates, Inc.			
Street Address 1		Street Address 2	
9301 Amberglen Blvd		Suite 100	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Austin	TEXAS	78729	512-869-1555
3. Related Persons			
Last Name	First Name		Middle Name
Poma	Eric		E.
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Bl		
City	State/Province/Co	untry	ZIP/PostalCode
Austin	TEXAS		78729
Relationship: X Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name		Middle Name
Selick	Harold		E.
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Bl	vd, Suite 100	
City	State/Province/Co	untry	ZIP/PostalCode
Austin	TEXAS		78729
Relationship: Executive Officer	N Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name		Middle Name
Gruia	Gabriela		
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Bl	vd, Suite 100	
City	State/Province/Co	untry	ZIP/PostalCode
Austin	TEXAS		78729
Relationship: Executive Officer	X Director Promoter		

Clarification of Response (if Necessar	у):		
Last Name	First Name	Middle Name	
Hoffmann	David		
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Blvd, Suite 100		
City	State/Province/Country	ZIP/PostalCode	
Austin	TEXAS	78729	
		18129	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	y):		
Last Name	First Name	Middle Name	
Lalande	Kevin		
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Blvd, Suite 100		
City	State/Province/Country	ZIP/PostalCode	
Austin	TEXAS	78729	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	у):		
Last Name	First Name	Middle Name	
Lanfear	Jonathan		
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Blvd, Suite 100		
City	State/Province/Country	ZIP/PostalCode	
Austin	TEXAS	78729	
Relationship: Executive Officer X		70725	
Clarification of Response (if Necessar			
Last Name	First Name	Middle Name	
Sanders	Corsee	Wildie Hame	
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Blvd, Suite 100		
		ZIP/PostalCode	
City	State/Province/Country TEXAS	78729	
Austin  Relationship: Executive Officer X		78729	
Clarification of Response (if Necessar			
Last Name	First Name	Middle Name	
Kim	Jason		
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Blvd, Suite 100		
City	State/Province/Country	ZIP/PostalCode	
Austin	TEXAS	78729	
Relationship: X Executive Officer L	Director Promoter		
Clarification of Response (if Necessar	у):		
Last Name	First Name	Middle Name	
Waltzman	Roger	J.	
Street Address 1	Street Address 2		
c/o Molecular Templates, Inc.	9301 Amberglen Blvd, Suite 100		
City	State/Province/Country	ZIP/PostalCode	
Austin	TEXAS	78729	
Relationship: X Executive Officer [	Director Promoter		
Clarification of Response (if Necessar			
	•		
4. Industry Group			

Agriculture	Health Care	Retailing		
Banking & Financial Services	X Biotechnology	Restaurants		
Commercial Banking		Technology		
Insurance	Health Insurance	Computers		
Investing	Hospitals & Physicians	Telecommunications		
Investment Banking	Pharmaceuticals			
Pooled Investment Fund	Other Health Care	Other Technology		
Is the issuer registered as	Manufacturing	Travel		
an investment company under the Investment Company	Real Estate	∐ Airlines & Airports		
Act of 1940?	Commercial	Lodging & Conventions		
YesNo		Tourism & Travel Services		
Other Banking & Financial Services	Construction	Other Travel		
Business Services	REITS & Finance	Other		
Energy	Residential	Guici		
Coal Mining	Other Real Estate			
Electric Utilities	_			
Energy Conservation				
Environmental Services				
□ □Oil & Gas				
Other Energy				
5. Issuer Size				
	A	A		
Revenue Range OR  No Revenues	— — · · · ·	Asset Value Range e Net Asset Value		
\$1 - \$1,000,000	\$1 - \$5,000,0			
\$1,000,001 - \$5,000,000	\$5,000,001 -			
\$5,000,001 - \$25,000,000	<b>=</b>	- \$50,000,000		
\$25,000,001 - \$100,000,000	H	- \$100,000,000		
Over \$100,000,000	<b>=</b>			
X Decline to Disclose	Over \$100,000,000  Decline to Disclose			
Not Applicable	Not Applicable			
5. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)				
o. Federal Exemption(s) and Exclusion(s)	Claimed (Select all that app	ny)		
	Investme	nt Company Act Section 3(c)		
П	Section 3	(c)(1) Section 3(c)(9)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3	(c)(2) Section 3(c)(10)		
Rule 504 (b)(1)(i)	Section 3			
Rule 504 (b)(1)(ii)				
Rule 504 (b)(1)(iii)  X Rule 506(b)	Section 3			
Rule 506(c)	Section 3	(c)(5) Section 3(c)(13)		
Securities Act Section 4(a)(5)	Section 3	(c)(6) Section 3(c)(14)		
	Section 3	(c)(7)		
7. Type of Filing				
X New Notice Date of First Sale 2023-07-17  Amendment	First Sale Yet to Occur			
8. Duration of Offering				

Does the Issuer intend this offering to last more than one year? XYes No				
9. Type(s) of Securities Offered (select all that apply)				
X Equity Debt X Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other FAcquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Right to Other (describe)			
10. Business Combination Transaction				
Is this offering being made in connection with a business combination to or exchange offer?	ransaction, such as a merger, acquisition Yes X No			
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investor \$0 USD				
12. Sales Compensation				
Recipient	Recipient CRD Number None			
Stifel, Nicolaus & Company, Incorporated  (Associated) Broker or Dealer X None	793 (Associated) Broker or Dealer CRD Number $\overline{X}$ None			
	None			
None Street Address 1 745 7th Avenue City	Street Address 2 State/Province/Country	ZIP/Postal Code		
New York	NEW YORK	10019		
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US			
CALIFORNIA  CONNECTICUT  MASSACHUSETTS  NEW YORK				
13. Offering and Sales Amounts				
Total Offering Amount \$90,738,000 USD or Indefinite  Total Amount Sold \$19,999,998 USD  Total Remaining to be Sold \$70,738,002 USD or Indefinite				
Clarification of Response (if Necessary):				
Total offering amount includes the \$0.125 per underlying share of common sto conditions are met, and the aggregate exercise price of such warrants.	ock for warrants to purchase common stock to be issued in a sec	cond closing, assuming certain		
14. Investors				
Select if securities in the offering have been or may be sold to person such non-accredited investors who already have invested in the offer Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	ering. pe sold to persons who do not qualify as accredited invest			
15. Sales Commissions & Finder's Fees Expenses				
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not ki	nown, provide an estimate and		
Sales Commissions \$2,700,000 USD X Estimate				
Finders' Fees \$0 USD Estimate				
Clarification of Response (if Necessary):				
16. Use of Proceeds				

executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0	USD	Estimate
Ψυ	USD	

Clarification of Response (if Necessary):

#### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the
  accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Molecular Templates, Inc.	/s/ Eric E. Poma, Ph.D.	Eric E. Poma, Ph.D.	Chief Executive Officer	2023-07-26

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.